卡培他滨在晚期乳腺癌应用.pptVIP

Confirmed overall response rates were similar in the Xeloda and PLD arms (13.2% vs. 11%, P=0.64). 52% of patients in the PLD arm had confirmed stable disease compared with 45% in the Xeloda arm. 42% of patients in the Xeloda arm had confirmed progressive disease compared with 37% in the PLD arm. Al-Bartran S, et al. ASCO 2010 (Abst 1022) Time to progression was significantly longer in Xeloda-treated patients who had not received prior adjuvant anthracycline than in those who had received prior treatment (9 months vs. 5 months; P=0.0207). There was no significant difference in the TTP in the PLD treatment arm with respect to prior adjuvant treatment with anthracycline. Al-Bartran S, et al. ASCO 2010 (Abst 1022) Significantly more patients in the Xeloda arm experienced 3级/4 diarrhoea than in the PLD arm (12% vs. 0%, P=0.0002). 3级/4 thromboembolic events were significantly higher in the Xeloda arm, with 10% of patients affected compared with 2% or patients in the PLD arm (P=0.0333). Levels of 3级/4 hand-foot syndrome and cardiac events were not significantly different between the treatment arms. Al-Bartran S, et al. ASCO 2010 (Abst 1022). Xeloda and PLD demonstrated similar efficacy when used as first-line treatment in patients with MBC. Median TTP was 7 months in the Xeloda arm and 6 months in the PLD arm. Median overall survival was 29 months in the Xeloda arm and 23 months in the PLD arm. Both treatment regimens were generally well tolerated but with different toxicity profiles. The was less diarrhoea and fewer thromboembolic events in the PLD arm than in the Xeloda arm, but there was more luekopenia and mucositis. Al-Bartran S, et al. ASCO 2010 (Abst 1022). * A phase III trial comparing gemcitabine plus docetaxel (GT) and XT, with planned crossover to the alternate single agent, is currently ongoing. Patients with locally advanced or MBC with possible prior adjuvant or neoadjuvant taxane therapy, but no prior taxane therapy for MBC, were eligible